Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
Zbigniew Siudak1, Tomasz Rakowski, Artur Dziewierz
1Institute of Cardiology, Collegium Medicum, Jagiellonian University, Krakow, Poland. zbigniew.siudak@gmail.com
Insights
Early administration of abciximab in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) is linked to improved survival. This study highlights the benefit of early abciximab treatment in STEMI networks.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Primary percutaneous coronary intervention (PCI) is the standard reperfusion therapy for ST-elevation myocardial infarction (STEMI).
- Abciximab is a commonly used adjunct in primary PCI, but its optimal administration timing remains debated.
- Previous studies on abciximab timing in STEMI have yielded conflicting results.
Purpose of the Study:
- To investigate the impact of early versus late abciximab administration on one-year mortality in STEMI patients undergoing primary PCI.
- To analyze the effectiveness of early abciximab administration within STEMI networks.
Main Methods:
- A retrospective analysis of 1,650 STEMI patients from the EUROTRANSFER Registry across 15 PCI centers in seven European countries.
- Patients were categorized into early abciximab (EA) administration (≥30 minutes before first balloon) and late abciximab (LA) administration groups.
- One-year clinical follow-up data was collected and propensity score methods were used for adjustment.
Main Results:
- One-year mortality was significantly lower in the EA group (5.8%) compared to the LA group (10.3%) (p = 0.007).
- Propensity score adjustment confirmed a favorable outcome for EA administration (p = 0.004).
- A minority of patients (36%) received PCI within the recommended 90-minute time window.
Conclusions:
- Early administration of abciximab in STEMI patients undergoing primary PCI is associated with reduced one-year mortality.
- These findings support the early use of abciximab in STEMI hospital networks for improved patient outcomes.
- Timely treatment within recommended windows remains a challenge in STEMI care.
Background:
Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results.
Methods:
Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness).
Results:
Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abciximab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay).
Conclusions:
Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies